Advance in Reversible Covalent Kinase Inhibitors
暂无分享,去创建一个
[1] J. M. Bradshaw,et al. Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib). , 2022, Journal of medicinal chemistry.
[2] R. Roskoski. Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update. , 2021, Pharmacological research.
[3] D. Murrell,et al. Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus , 2021, Frontiers in Medicine.
[4] D. Fabbro,et al. Trends in kinase drug discovery: targets, indications and inhibitor design , 2021, Nature Reviews Drug Discovery.
[5] Jiahua Rao,et al. Quantitative evaluation of explainable graph neural networks for molecular property prediction , 2021, Patterns.
[6] P. Jänne,et al. Kinase drug discovery 20 years after imatinib: progress and future directions , 2021, Nature Reviews Drug Discovery.
[7] Colin J. Daniel,et al. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo , 2021, Nature Chemical Biology.
[8] R. Roskoski. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. , 2021, Pharmacological research.
[9] Rong Li,et al. Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL Inhibitors. , 2021, Angewandte Chemie.
[10] Chris de Graaf,et al. KLIFS: an overhaul after the first 5 years of supporting kinase research , 2020, Nucleic Acids Res..
[11] Derek J. Essegian,et al. The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer , 2020, Cell reports. Medicine.
[12] W. Jahnke,et al. Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. , 2020, Journal of medicinal chemistry.
[13] G. Keserű,et al. An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases. , 2020, European journal of medicinal chemistry.
[14] D. Murrell,et al. Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus. , 2020, Veterinary dermatology.
[15] S. Constantinescu,et al. Advances in covalent kinase inhibitors. , 2020, Chemical Society reviews.
[16] S. Meroueh,et al. Small-molecule covalent bond formation at tyrosine creates a binding site and inhibits activation of Ral GTPases , 2020, Proceedings of the National Academy of Sciences.
[17] S. Albeck,et al. Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs , 2020, Journal of the American Chemical Society.
[18] Michael L. Wang,et al. Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry , 2019, Nature Communications.
[19] N. Gray,et al. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation. , 2019, Cell chemical biology.
[20] J. Irwin,et al. Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking. , 2019, Journal of the American Chemical Society.
[21] Kathryn A. Porter,et al. Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases. , 2019, Journal of medicinal chemistry.
[22] W. Liu,et al. Covalent Inhibition in Drug Discovery , 2019, ChemMedChem.
[23] I. E. Smith,et al. PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding. , 2019, ACS chemical biology.
[24] S. Laufer,et al. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. , 2018, Journal of medicinal chemistry.
[25] M. Ono,et al. Selective and reversible modification of kinase cysteines with chlorofluoroacetamides , 2019, Nature Chemical Biology.
[26] Daniel P. Walker,et al. Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning. , 2018, ACS medicinal chemistry letters.
[27] Yan Li,et al. Comparative Assessment of Scoring Functions: The CASF-2016 Update , 2018, J. Chem. Inf. Model..
[28] P. Bourne,et al. Overview of Current Type I/II Kinase Inhibitors , 2018, Next Generation Kinase Inhibitors.
[29] J. Bauman,et al. Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors. , 2018, Journal of medicinal chemistry.
[30] M. Katoh. Fibroblast growth factor receptors as treatment targets in clinical oncology , 2018, Nature Reviews Clinical Oncology.
[31] G. F. Ruda,et al. Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening , 2018, bioRxiv.
[32] N. Westwood,et al. The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1. , 2018, Cell chemical biology.
[33] W. Fast,et al. The Taxonomy of Covalent Inhibitors. , 2018, Biochemistry.
[34] S. Knapp,et al. The Cysteinome of Protein Kinases as a Target in Drug Development. , 2018, Angewandte Chemie.
[35] N. Gray,et al. Kinase inhibitors: the road ahead , 2018, Nature Reviews Drug Discovery.
[36] Philip E Bourne,et al. Progress with covalent small-molecule kinase inhibitors. , 2018, Drug discovery today.
[37] H. Rupasinghe,et al. Kinase-targeted cancer therapies: progress, challenges and future directions , 2018, Molecular Cancer.
[38] K. Kang,et al. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer , 2018, Molecular Cancer Therapeutics.
[39] P. Furet,et al. 2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4. , 2018, ACS medicinal chemistry letters.
[40] J. M. Bradshaw,et al. PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen‐1 signalling , 2018, British journal of pharmacology.
[41] J. Funk,et al. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers , 2017, British journal of clinical pharmacology.
[42] P. Furet,et al. Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region. , 2017, MedChemComm.
[43] L. Olsen,et al. Aldehyde Oxidase: Reaction Mechanism and Prediction of Site of Metabolism , 2017, ACS omega.
[44] K. Shokat,et al. Drugging the 'undruggable' cancer targets , 2017, Nature Reviews Cancer.
[45] D. Rauh,et al. Characterization of Covalent-Reversible EGFR Inhibitors , 2017, ACS omega.
[46] P. Bourne,et al. Determining Cysteines Available for Covalent Inhibition Across the Human Kinome. , 2017, Journal of medicinal chemistry.
[47] N. Turner,et al. Advances and challenges in targeting FGFR signalling in cancer , 2017, Nature Reviews Cancer.
[48] Tudor I. Oprea,et al. A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.
[49] S. Knapp,et al. Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket , 2016, Cell chemical biology.
[50] T. Baillie,et al. Targeted Covalent Inhibitors for Drug Design. , 2016, Angewandte Chemie.
[51] R. Zahedi,et al. Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR. , 2016, Angewandte Chemie.
[52] N. Hannett,et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. , 2016, Nature chemical biology.
[53] R. Obach,et al. Intrinsic reactivity profile of electrophilic moieties to guide covalent drug design: N-α-acetyl-L-lysine as an amine nucleophile , 2016 .
[54] A. Olson,et al. Proteome-wide covalent ligand discovery in native biological systems , 2016, Nature.
[55] H. Gharwan,et al. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications , 2016, Nature Reviews Clinical Oncology.
[56] Zheng Zhao,et al. Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach. , 2016, Journal of medicinal chemistry.
[57] S. Knapp,et al. The ins and outs of selective kinase inhibitor development. , 2015, Nature chemical biology.
[58] Chengbo Zhan,et al. Access to a new class of synthetic building blocks via trifluoromethoxylation of pyridines and pyrimidines , 2015, Chemical science.
[59] Megan Cully. Rational drug design: Tuning kinase inhibitor residence time , 2015, Nature reviews. Drug discovery.
[60] D. Rauh,et al. Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR. , 2015, Bioorganic & medicinal chemistry.
[61] J. M. Bradshaw,et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors , 2015, Nature chemical biology.
[62] George Papadatos,et al. ChEMBL web services: streamlining access to drug discovery data and utilities , 2015, Nucleic Acids Res..
[63] Pengyu Y. Ren,et al. Reversible Covalent Inhibition of eEF‐2K by Carbonitriles , 2014, Chembiochem : a European journal of chemical biology.
[64] Nir London,et al. Covalent Docking of Large Libraries for the Discovery of Chemical Probes , 2014, Nature chemical biology.
[65] J. Taunton,et al. Design of Reversible, Cysteine-Targeted Michael Acceptors Guided by Kinetic and Computational Analysis , 2014, Journal of the American Chemical Society.
[66] Tove Tuntland,et al. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research , 2014, Front. Pharmacol..
[67] S. Knapp,et al. Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? , 2014, ACS chemical biology.
[68] P. Kuzmič,et al. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance , 2013, Proceedings of the National Academy of Sciences.
[69] S. Frye,et al. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. , 2013, Journal of medicinal chemistry.
[70] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[71] Jack Taunton,et al. Electrophilic fragment-based design of reversible covalent kinase inhibitors. , 2013, Journal of the American Chemical Society.
[72] Nathanael S Gray,et al. Developing irreversible inhibitors of the protein kinase cysteinome. , 2013, Chemistry & biology.
[73] Pedro M. P. Gois,et al. Iminoboronates: a new strategy for reversible protein modification. , 2012, Journal of the American Chemical Society.
[74] Jack Taunton,et al. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles , 2012, Nature chemical biology.
[75] Adrian Whitty,et al. The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.
[76] F. Fleming,et al. Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. , 2010, Journal of medicinal chemistry.
[77] B. Brandhuber,et al. Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition , 2010, PloS one.
[78] David Baker,et al. Quantitative reactivity profiling predicts functional cysteines in proteomes , 2010, Nature.
[79] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[80] P. Majumder,et al. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.
[81] Scott B Ficarro,et al. A structure-guided approach to creating covalent FGFR inhibitors. , 2010, Chemistry & biology.
[82] John T. Powers,et al. Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.
[83] John R. Engen,et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.
[84] Adele Di Matteo,et al. Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases. , 2009, Cancer research.
[85] Andrew G. Leach,et al. Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. , 2009, Journal of medicinal chemistry.
[86] R. Copeland,et al. Residence time of receptor-ligand complexes and its effect on biological function. , 2008, Biochemistry.
[87] F. Sicheri. Faculty Opinions recommendation of Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. , 2007 .
[88] T. Zhou,et al. Crystal Structure of the T315I Mutant of Abl Kinase , 2007, Chemical biology & drug design.
[89] R. Copeland,et al. Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.
[90] Jean-François Truchon,et al. A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. , 2007, Bioorganic & medicinal chemistry letters.
[91] Jeffrey Jie-Lou Liao,et al. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. , 2007, Journal of medicinal chemistry.
[92] Michael S. Cohen,et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors , 2005, Science.
[93] A. Siraki,et al. Aldehyde Sources, Metabolism, Molecular Toxicity Mechanisms, and Possible Effects on Human Health , 2005, Critical reviews in toxicology.
[94] O. Silvennoinen,et al. The Janus kinases (Jaks) , 2004, Genome Biology.
[95] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[96] J. Powers,et al. Irreversible inhibitors of serine, cysteine, and threonine proteases. , 2002, Chemical reviews.
[97] P. Cohen,et al. The origins of protein phosphorylation , 2002, Nature Cell Biology.
[98] J. Adams,et al. Kinetic and catalytic mechanisms of protein kinases. , 2001, Chemical reviews.
[99] D. Fairlie,et al. Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.
[100] J. Gierse,et al. Kinetic basis for selective inhibition of cyclo-oxygenases. , 1999, The Biochemical journal.
[101] Francois Terrier,et al. Rate and equilibrium studies in Jackson-Meisenheimer complexes , 1982 .
[102] H. L. Holmes,et al. Equilibrium reactions of n-butanethiol with some conjugated heteroenoid compounds , 1968 .
[103] N. Ormaechea-Pérez,et al. Adverse skin effects of imatinib, a tyrosine kinase inhibitor. , 2014, Actas dermo-sifiliograficas.
[104] N. Schork,et al. Kinase mutations in human disease: interpreting genotype–phenotype relationships , 2010, Nature Reviews Genetics.
[105] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.